RYTM Stock Jumps on Impressive Setmelanotide Data

RYTM stock

RYTM stock is making a solid move after Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) announced positive results from two Phase 3 clinical trials evaluating setmelanotide.

Key Development

When biotech companies receive positive news with regards to any of their medicines that are under development, then the stock price generally rises, and that is what happened this morning with micro-cap stock Rhythm Pharmaceuticals. Obesity is now a problem that has reached epidemic proportions, and the complications associated with it are well known. Rhythm is involved in manufacturing medicines for treating genetic disorders brought on by obesity.

Today, ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.